Ionis Pharmaceuticals, Inc.

848 articles with Ionis Pharmaceuticals, Inc.

• Ionis' Chief Scientific Officer C. Frank Bennett, Ph.D., receives Gabbay Award in Biotechnology and Medicine

  6/14/2021

  Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced that Executive Vice President and Chief Scientific Officer C. Frank Bennett, Ph.D., is a co-recipient of the 23rd Jacob and Louise Gabbay Award in Biotechnology and Medicine for his innovative work on antisense therapy.

• Ionis' antisense therapies in ATTR amyloidosis to be featured at 2021 PNS Annual Meeting

  6/10/2021

  Ionis Pharmaceuticals, Inc. (NASDAQ: IONS),  today announced that multiple presentations highlighting advances in its ATTR amyloidosis programs will be featured during the 2021 Peripheral Nerve Society (PNS) Annual Meeting to be held virtually on June 12-13, and 25-27, 2021.

• Ionis announces changes to its board of directors at annual meeting of stockholders

  6/3/2021

  Ionis Pharmaceuticals, Inc. announced changes to its board of directors. Joseph Loscalzo, M.D., Ph.D., has been appointed chairman of the board and Allene M. Diaz has been appointed to the board.

• Ionis to present at upcoming investor conferences - May 26, 2021

  5/26/2021

  Ionis Pharmaceuticals, Inc. announced that management will present a company overview at the following virtual investor conferences

• Ionis to present at upcoming investor conferences - May 06, 2021

  5/6/2021

  Ionis Pharmaceuticals, Inc. announced that management will participate in virtual fireside chats at the following investor conferences

• Ionis to host 2021 virtual annual meeting of stockholders

  5/5/2021

  Ionis Pharmaceuticals, Inc. announced that management will conduct its 2021 virtual Annual Meeting of Stockholders followed by a general corporate update on Wednesday, June 2, 2021.

• Ionis reports first quarter 2021 financial results and recent business achievements

  5/5/2021

  On track to achieve 2021 guidance Webcast today, May 5, 2021, at 11:30 a.m. Eastern Time

• 

  Ceding to Pressure, Biogen Will Offer Early Access to Tofersen in July

  4/27/2021

  In phase one of the two-part program, access to tofersen will be granted on an individual basis to SOD1-ALS patients with an ALS Functional Rating Scale - Revised (ALSFRS-R) slope decline greater than or equal to 2 points per month.

• Ionis to hold first quarter 2021 financial results webcast

  4/21/2021

   Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Wednesday, May 5 th at 11:30 a.m. Eastern Time to discuss its first quarter 2021 financial results and report on pipeline and business product

• Ionis initiates pivotal clinical study of novel antisense medicine to treat patients with Alexander disease

  4/20/2021

  Innovative therapy targeting the root cause of the disease has received orphan drug designation by the U.S. FDA and European Medicines Agency

• 

  Clinical Catch-Up: April 5-9

  4/12/2021

  It was a relatively quiet week for clinical trial announcements, but there were a few standouts. Read on for more.

• Non-profit Partnership Spurs Phase 3 Clinical Trial for Patients With Rare Genetic Form Of ALS

  4/8/2021

  Ionis Pharmaceuticals announces pivotal patient trial of antisense therapy following aggressive joint research effort led by the non-profits The ALS Association and Project ALS.

• Ionis prices private placement of convertible senior notes

  4/8/2021

  Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today the pricing of $550.0 million aggregate principal amount of 0% Convertible Senior Notes due 2026

• 

  Ionis' Ups and Downs: Partnership with Progenity, 70% Job Cuts at Akcea and More

  4/7/2021

  Ionis Pharmaceuticals unleashed a string of news releases about activities at the company, including a partnership with Progenity and the launch of a Phase III trial for amyotrophic lateral sclerosis.

• Ionis announces proposed private placement of convertible notes

  4/6/2021

   Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it intends to offer, subject to market conditions and other factors, $500.0 million aggregate principal amount of Convertible Senior Notes due 2026 (the "notes") in a private placement (the "offering") to qualified institutional buyers pursuant to Rule 144A

• Progenity and Ionis Pharmaceuticals Enter into Agreement to Evaluate Progenity’s Ingestible Oral Biotherapeutics Technology for Delivery of Antisense Therapies

  4/6/2021

  Progenity , Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success developing and commercializing molecular testing products, today announced an agreement with Ionis Pharmaceuticals, the leader in RNA-targeted therapeutics, to evaluate the safety, tolerability and performance of Progenity’s Oral Biotherapeutics Delivery System (OBDS) for oral systemic delivery of antisense oligonucleotides

• Ionis initiates Phase 3 trial of novel antisense medicine to treat leading cause of juvenile-onset ALS

  4/5/2021

  ION363, the first medicine to specifically target FUS-ALS, is among Ionis' wholly owned assets the company plans to commercialize

• Ionis reports positive topline Phase 2 study results of its novel antisense treatment for hereditary angioedema

  3/29/2021

  - IONIS-PKK-L Rx met its primary and all secondary endpoints, including a mean reduction of up to 97% in HAE attacks compared to placebo

• 

  Clinical Catch-Up: March 22-26

  3/29/2021

  There was a fair amount of clinical trial news last week. Here’s a look.

• Ionis to present at upcoming investor conferences - Mar 26, 2021

  3/26/2021

  Ionis Pharmaceuticals, Inc., the leader in RNA-targeted therapeutics, announced that management will participate in virtual fireside chats at the following investor conferences